Transaction DateRecipientSharesTypePriceValue
17th September 2020Suma Krishnan1,126Open or private sale$47.29$53,248.31
17th September 2020Suma Krishnan7,437Open or private sale$46.63$346,813.34
17th September 2020Suma Krishnan10,594Open or private sale$46.09$488,296.53
16th September 2020Suma Krishnan9,749Open or private sale$46.24$450,821.06
16th September 2020Suma Krishnan5,142Open or private sale$46.85$240,895.50
15th September 2020Suma Krishnan14,435Open or private sale$46.21$667,031.25
15th September 2020Suma Krishnan1,517Open or private sale$47.15$71,523.21
29th June 2020Antony A Riley2,000Open or private purchase$14.11$28,220.00
26th June 2020Antony A Riley4,700Open or private purchase$14.52$68,225.20
15th June 2020Suma Krishnan8,652Open or private sale$42.24$365,426.74
Krystal Biotech
Krystal Biotech logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Krystal Biotech, Inc. engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform.

Ticker: KRYS
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1711279
Employees: 37
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags